Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
 
  • Details

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Journal
Hepatology
Journal Volume
47
Journal Issue
3
Pages
844-853
Date Issued
2008
Author(s)
CHIUN HSU  
Hsiung C.A.
Su I.-J.
Hwang W.-S.
Wang M.-C.
Lin S.-F.
Lin T.-H.
Hsiao H.-H.
Young J.-H.
Chang M.-C.
Liao Y.-M.
Li C.-C.
Wu H.-B.
HWEI-FANG TIEN  
Chao T.-Y.
Liu T.-W.
ANN-LII CHENG  
PEI-JER CHEN  
DOI
10.1002/hep.22106
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-40949125163&doi=10.1002%2fhep.22106&partnerID=40&md5=f334d44937cb77b5e346d7e5ae4bc5d2
https://scholars.lib.ntu.edu.tw/handle/123456789/537498
Abstract
Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined. In this study, HBV carriers with newly diagnosed non-Hodgkin's lymphoma (NHL) who underwent chemotherapy were randomized to either prophylactic (P) or therapeutic (T) lamivudine treatment groups. Group P patients started lamivudine from day 1 of the first course of chemotherapy and continued treatment until 2 months after completion of chemotherapy. Group T patients received chemotherapy alone and started lamivudine treatment only if serum alanine aminotransferase (ALT) levels elevated to greater than 1.5-fold of the upper normal limit (ULN). The primary endpoint was incidence of HBV reactivation during the 12 months after starting chemotherapy. During chemotherapy, fewer group P patients had HBV reactivation (11.5% versus 56%, P = 0.001), HBV-related hepatitis (7.7% versus 48%, P = 0.001), or severe hepatitis (ALT more than 10-fold ULN) (0 versus 36%, P < 0.001). No hepatitis-related deaths occurred during protocol treatment. Prophylactic lamivudine use was the only independent predictor of HBV reactivation. After completion of chemotherapy, the incidence of HBV reactivation did not differ between the 2 groups. Two patients, both in group P, died of HBV reactivation-related hepatitis, 173 and 182 days, respectively, after completion of protocol treatment. When compared with an equivalent group of lamivudine-na?ve lymphoma patients who underwent chemotherapy, therapeutic use of lamivudine neither reduced the severity of HBV-related hepatitis nor changed the patterns of HBV reactivation. Conclusion: Prophylactic lamivudine use, but not therapeutic use, reduces the incidence and severity of chemotherapy-related HBV reactivation in NHL patients. Copyright ? 2007 by the American Association for the Study of Liver Diseases.
SDGs

[SDGs]SDG3

Other Subjects
alanine aminotransferase; antineoplastic agent; cyclophosphamide; doxorubicin; lamivudine; prednisolone; vincristine; antivirus agent; lamivudine; adolescent; adult; aged; alanine aminotransferase blood level; article; bone marrow suppression; cancer chemotherapy; clinical protocol; clinical trial; comparative study; controlled clinical trial; controlled study; disease severity; female; hepatitis B; Hepatitis B virus; human; incidence; infection prevention; infection risk; liver failure; major clinical study; male; multiple cycle treatment; nonhodgkin lymphoma; prediction; priority journal; randomization; randomized controlled trial; risk reduction; side effect; treatment duration; virus carrier; virus reactivation; hepatitis B; middle aged; mortality; nonhodgkin lymphoma; recurrent disease; survival; treatment outcome; Adult; Aged; Antiviral Agents; Female; Hepatitis B; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome
Publisher
John Wiley and Sons Ltd
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science